Fibrilación auricular y terapéutica anticoagulante
Atrial fibrillation is the most frequent arrhythmia in general population. Its frequency increases with age, being 1.5% from 50 to 59 years old and 8-10% from 80 to 89 years old. Atrial fibrillation increases 5 fold the risk of suffering a stroke and causes 15% of all strokes. Atrial fibrillation...
Guardado en:
| Publicado en: | Revista Médica Universitaria |
|---|---|
| Autores principales: | , |
| Materias: | |
| Acceso en línea: | https://bdigital.uncu.edu.ar/fichas.php?idobjeto=3196 |
| Sumario: | Atrial fibrillation is the most frequent arrhythmia in general population. Its frequency
increases with age, being 1.5% from 50 to 59 years old and 8-10% from 80 to 89
years old. Atrial fibrillation increases 5 fold the risk of suffering a stroke and causes
15% of all strokes. Atrial fibrillation management focuses in the prevention of
thromboembolic phenomena and heart rate and rhythm control. Anticoagulation, when
is indicated, has demonstrated to be the main tool in the prevention of these
thromboembolic events. Although bleeding complications are frequent in this
population and increase with age, anticoagulation benefits are greater than the risks of
bleeding. Due to the clinically heterogeneous nature of this arrythmia and the difficulty
of establishing appropriate treatment for each particular case, the American College of
Cardiology, the American Heart Association, European Society of Cardiology and
American College of Chest Physicians have established guidelines to improve the
management these patients. The review of thist condition and the proposed directives
can notably facilitate and improve the mangement of the patients with atrial fibrillation.
|
|---|
